The Biology of VWF Self-Association

Information

  • Research Project
  • 9533694
  • ApplicationId
    9533694
  • Core Project Number
    R01HL137991
  • Full Project Number
    5R01HL137991-02
  • Serial Number
    137991
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    9/1/2017 - 7 years ago
  • Project End Date
    6/30/2020 - 4 years ago
  • Program Officer Name
    WARREN, RONALD Q
  • Budget Start Date
    7/1/2018 - 6 years ago
  • Budget End Date
    6/30/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/29/2018 - 6 years ago
Organizations

The Biology of VWF Self-Association

Project Summary  von  Willebrand  factor  (VWF)  is  a  multimeric  glycoprotein  in  plasma  that  plays  an  important  role  in  hemostasis  by  mediating  platelet  binding  to  sites  of  vascular  injury.  In  recent  studies,  VWF has also been implicated in microvascular dysfunction and occlusion, in part because of its  unique  ability  to  self?associate  and  form  hyperadhesive  strands  of  enormous  sizes  attached  to  the  endothelial  surface  in  response  to  hydrodynamic  forces,  including  shear  stress  and  elongation  flow.  When  these  hyperadhesive  strands  are  not  removed  by  the  metalloprotease  ADAMTS13  in  plasma,  they  bind  platelets  efficiently,  and  the  accumulation  of  VWF?platelet  thrombi  leads  to  vessel  occlusion,  tissue  infarction,  and  organ  dysfunction.  We  recently  discovered  that  high  density  lipoprotein  (HDL),  a  well?known  cardioprotective  lipoprotein  in  plasma, and its major component protein apolipoprotein (Apo)A?I, can attenuate the extent of  VWF  self?association,  and  ultimately  the  severity  of  thrombotic  complications  in  the  vasculature. These studies unveiled a novel antithrombotic property of HDL/ApoA?I, which we  hypothesize  is  very  important  in  diseases  characterized  by  microvascular  occlusion.  In  this  application, we will focus on the mechanism of VWF self?association, how VWF interacts with  HDL/ApoA?I,  and  the  physiologic  impact  of  the  HDL?VWF  interaction.  In  Specific  Aim  1,  we  will  identify  the  VWF  self?association  site  exposed  by  hydrodynamic  forces  by  use  of  VWF  variants  and  peptide  mapping.  In  Specific  Aim  2,  we  will  determine  the  effect  of  VWF  self? association on ADAMTS13?mediated cleavage under shear stress, and assess the role of HDL in  ADAMTS13?mediated  cleavage  of  VWF  in  tubes  and  devices  with  newly?developed  non? adsorptive  coatings.  In  Specific  Aim  3,  we  will  evaluate  in  mouse  models  of  thrombotic  microangiopathy and thrombotic thrombocytopenic purpura whether the outcome and disease  parameters  are  worsened  by  HDL  or  ADAMTS13  deficiency,  or  improved  by  HDL  or  ADAMTS13  treatment.  Successful  completion  of  these  aims  will  provide  an  improved  understanding  of  the  basic  mechanism  of  VWF  self?association,  how  this  process  can  be  regulated, and how this information can be used to develop new approaches to treat thrombotic  diseases caused by dysregulation of VWF self?association.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    368157
  • Indirect Cost Amount
    304834
  • Total Cost
    672991
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:672991\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HT
  • Study Section Name
    Hemostasis and Thrombosis Study Section
  • Organization Name
    PUGET SOUND BLOOD CENTER
  • Organization Department
  • Organization DUNS
    092881085
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981041239
  • Organization District
    UNITED STATES